Enoximone
- Generic Name
- Enoximone
- Drug Type
- Small Molecule
- Chemical Formula
- C12H12N2O2S
- CAS Number
- 77671-31-9
- Unique Ingredient Identifier
- C7Z4ITI7L7
- Background
Enoximone is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with congestive heart failure. Trials were halted in the U.S., but the drug is used in various countries.
- Indication
For the treatment of congestive heart failure.
- Associated Conditions
- Congestive Heart Failure (CHF)
The Effects of Enoximone in Acute Exacerbation COPD
Phase 4
Terminated
- Conditions
- COPD ExacerbationEnoximonePhosphodiesterase Inhibitor
- Interventions
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- Rijnstate Hospital
- Target Recruit Count
- 3
- Registration Number
- NCT04420455
- Locations
- 🇳🇱
M.V. Koning, Arnhem, M, Netherlands
Microcirculation Guided Therapy Versus "Standard Treatment" of Severe Sepsis
Phase 4
- Conditions
- Severe SepsisMicrocirculation
- First Posted Date
- 2007-06-08
- Last Posted Date
- 2008-01-22
- Lead Sponsor
- Onze Lieve Vrouwe Gasthuis
- Target Recruit Count
- 80
- Registration Number
- NCT00484133
- Locations
- 🇳🇱
Onze Lieve Vrouwe Gasthuis, intensive care, Amsterdam, Netherlands
Enoximone Plus Extended-Release Metoprolol Succinate in Subjects With Advanced Chronic Heart Failure
Phase 3
Terminated
- Conditions
- Heart Failure, Congestive
- Interventions
- First Posted Date
- 2004-02-18
- Last Posted Date
- 2014-01-10
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 175
- Registration Number
- NCT00077948
- Locations
- 🇺🇸
University of Utah, Salt Lake City, Utah, United States
🇺🇸University of Colorado, Denver, Colorado, United States
ESSENTIAL-"The Studies of Oral Enoximone Therapy in Advanced Heart Failure"
Phase 3
Terminated
- Conditions
- Heart Failure, Congestive
- Interventions
- First Posted Date
- 2003-01-09
- Last Posted Date
- 2014-01-10
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 1800
- Registration Number
- NCT00051285
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath